VYNE Therapeutics to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event this Week
05 janv. 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will participate...
VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in Acne
17 déc. 2020 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) , a specialty pharmaceutical company focused on developing and commercializing...
VYNE Therapeutics Added to Nasdaq Biotechnology Index
16 déc. 2020 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE”), a specialty pharmaceutical company focused on developing and commercializing proprietary...
VYNE Therapeutics Announces New U.S. Patent Expiring in 2037 for AMZEEQ® (minocycline) topical foam, 4%
15 déc. 2020 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing...
VYNE Therapeutics Announces Publication of Long-term Safety & Efficacy Data for ZILXI™ (minocycline) topical foam, 1.5% in the Journal of Clinical and Aesthetic Dermatology
01 déc. 2020 08h00 HE
|
VYNE Therapeutics Inc.
ZILXI is the First FDA Approved Minocycline Product for the Treatment of Inflammatory Lesions of Rosacea in AdultsZILXI demonstrated a favorable safety and tolerability profile for up to 52 weeks of...
VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference
25 nov. 2020 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will participate...
VYNE Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
05 nov. 2020 07h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the third quarter ended September 30, 2020...
VYNE Therapeutics to Report Third Quarter 2020 Financial Results on November 5th
28 oct. 2020 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third quarter...
VYNE Therapeutics Announces Covered Status for ZILXI™ (minocycline) with Express Scripts
07 oct. 2020 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced a coverage update for its novel ZILXI™ (minocycline) topical...
VYNE Therapeutics Announces ZILXI™ (minocycline) topical foam, 1.5% is Available in Pharmacies Nationwide Today, October 1st
01 oct. 2020 07h00 HE
|
VYNE Therapeutics Inc.
ZILXI is the First FDA Approved Minocycline Product for the Treatment of Inflammatory Lesions of Rosacea in Adults ZILXI Offers Efficacy with Low Systemic Absorption BRIDGEWATER, N.J., Oct. 01,...